Filing Flows › CV Sciences (CVSI) › Q2 2026 › vs Q1 2026
CV Sciences (CVSI) Q2 2026 vs Q1 2026 (quarter over quarter)
CV Sciences's revenue fell $210K (-7%) from $3.2M in Q1 2026 to $3.0M in Q2 2026.
CV Sciences, Q2 2026: revenue $3.0M (-18% year over year), operating margin -10.1%, net loss $775K, operating cash flow $20K. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 0.4% | 3.1% | -2.6 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $3.0M | $3.2M | −$210K | -7% |
| Net loss | $775K | $643K | $132K | +21% |
| Costs & expenses | $3.8M | $3.8M | −$78K | -2% |
| Operating costs | $3.3M | $3.5M | −$227K | -6% |
| Interest & other, net | $469K | $325K | $144K | +44% |
| Income tax | $5K | $0 | $5K | — |
| Cost of revenue | $1.5M | $1.6M | −$98K | -6% |
| Research & development | $18K | $18K | $0 | 0% |
| SG&A | $1.7M | $1.9M | −$129K | -7% |
| Operating cash sources | $795K | $744K | $51K | +7% |
| Depreciation & amortization | $22K | $23K | −$1K | -4% |
| Share-based compensation | $148K | $148K | $0 | 0% |
| Working capital & other | $625K | $573K | $52K | +9% |
| Net loss absorbed | $775K | $643K | $132K | +21% |
| Operating cash flow | $20K | $101K | −$81K | -80% |
| Free cash flow (OCF − capex) | $13K | $98K | −$85K | -87% |
| Capital expenditures | $7K | $3K | $4K | +133% |
Questions
How much did CV Sciences's revenue grow quarter over quarter in Q2 2026?
CV Sciences's revenue fell $210K (-7%) from $3.2M in Q1 2026 to $3.0M in Q2 2026.